KKR-backed Biosynth Carbosynth acquires vivitide
Global investment firm KKR has closed its previously announced investment in Biosynth Carbosynth, an life sciences reagents, custom synthesis and manufacturing services company, as well as Biosynth Carbosynth’s acquisition of vivitide, a global provider of custom peptides and antibodies for the life sciences and biotech industry. Existing vivitide owner Ampersand